United States - English - NLM (National Library of Medicine)

the ritedose corporation - albuterol sulfate (unii: 021sef3731) (albuterol - unii:qf8svz843e), ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) -

United States - English - NLM (National Library of Medicine)

the ritedose corporation - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) -

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide nasal solution 0.06% (nasal spray) is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children age 5 years and older. ipratropium bromide nasal solution 0.06% (nasal spray) does not relieve nasal congestion or sneezing associated with the common cold or seasonal allergic rhinitis. the safety and effectiveness of the use of ipratropium bromide nasal solution 0.06% (nasal spray) beyond four days in patients with the common cold or beyond three weeks in patients with seasonal allergic rhinitis has not been established. ipratropium bromide nasal solution 0.06% (nasal spray) is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients. ipratropium bromide nasal solution 0.06% (nasal spray) 42 mcg/spray rx only read complete instructions carefully before using. in order to ensure proper dosing, do not attempt to change the size of the spray ope

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium bromide - unii:j697uz2a9j) - ipratropium bromide nasal solution 0.06% (nasal spray) is indicated for the symptomatic relief of rhinorrhea associated with the common cold for adults and children age 5 years and older. ipratropium bromide nasal solution 0.06% (nasal spray) does not relieve nasal congestion or sneezing associated with the common cold or seasonal allergic rhinitis. the safety and effectiveness of the use of ipratropium bromide nasal solution 0.06% (nasal spray) beyond four days in patients with the common cold or beyond three weeks in patients with seasonal allergic rhinitis has not been established. ipratropium bromide nasal solution 0.06% (nasal spray) is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. atrovent hfa is contraindicated in the following conditions [see warnings and precautions (5.2) ]. - hypersensitivity to ipratropium bromide or other atrovent hfa components - hypersensitivity to atropine or any of its derivatives there are no adequate and well-controlled studies of atrovent hfa (ipratropium bromide) inhalation aerosol in pregnant women. atrovent hfa should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. oral reproduction studies were performed in mice, rats and rabbits at doses approximately 200, 40,000, and 10,000 times, respectively, the maximum recommended human daily inhalation dose (mrhdid) in adults (on a mg/m2 basis at maternal doses in each species of 10, 1,000, and 125 mg/kg/day, respectively). inhalation reproduction stu

United States - English - NLM (National Library of Medicine)

rpk pharmaceuticals, inc. - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - atrovent hfa inhalation aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. atrovent hfa is contraindicated in the following conditions [see warnings and precautions (5.2) ]. - hypersensitivity to ipratropium bromide or other atrovent hfa components - hypersensitivity to atropine or any of its derivatives risk summary ipratropium is negligibly absorbed systemically following oral inhalation; therefore, maternal use is not expected to result in fetal exposure to the drug [see clinical pharmacology (12.3)] . there is limited experience with ipratropium bromide use in pregnant women. published literature, including cohort studies, case control studies and case series, over several decades have not identified a drug associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. based on animal reproduction studies, no evidence of structural alteration

Ireland - English - HPRA (Health Products Regulatory Authority)

norton healthcare limited t/a ivax pharmaceuticals uk - ipratropium bromide - nebuliser solution - 250 microgram/ml - ipratropium bromide

Canada - English - Health Canada

pharmascience inc - ipratropium bromide - solution - 125mcg - ipratropium bromide 125mcg - antimuscarinics antispasmodics

Canada - English - Health Canada

pharmascience inc - ipratropium bromide - solution - 250mcg - ipratropium bromide 250mcg - antimuscarinics antispasmodics

Canada - English - Health Canada

pharmascience inc - ipratropium bromide - solution - 250mcg - ipratropium bromide 250mcg - antimuscarinics antispasmodics